Daniel Clark's most recent trade in Kiromic BioPharma Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Aug. 11, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kiromic BioPharma Inc | Daniel Clark | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Aug 2022 | 50,000 | 62,770 | - | 0 | Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 3,940 | 313,487 | - | - | Class A Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2022 | 3,940 | 47,289 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Sale of securities on an exchange or to another person at price $ 1.47 per share. | 25 Jul 2022 | 1,280 | 312,207 | - | 1.5 | 1,882 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Former Secretary and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 4,005 | 60,087 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Former Secretary and GC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 4,005 | 313,552 | - | - | Class A Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Former Secretary and GC | Sale of securities on an exchange or to another person at price $ 1.32 per share. | 01 Jul 2022 | 1,207 | 312,345 | - | 1.3 | 1,592 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Sale of securities on an exchange or to another person at price $ 2.18 per share. | 28 Apr 2022 | 1,212 | 309,547 | - | 2.2 | 2,643 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 3,940 | 51,229 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2022 | 3,940 | 310,759 | - | - | Class A Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2022 | 111,271 | 111,271 | - | - | Employee Stock Option (Right to Buy) | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2022 | 64,092 | 64,092 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Sale of securities on an exchange or to another person at price $ 2.84 per share. | 28 Jan 2022 | 1,512 | 306,819 | - | 2.8 | 4,298 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2022 | 3,940 | 55,139 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2022 | 3,940 | 308,331 | - | - | Class A Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 275,000 | 839,504 | - | - | Employee Stock Option (right to buy) | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.15 per share. | 14 Jan 2022 | 275,000 | 281,391 | - | 0.2 | 42,048 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 97,142 | 97,142 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 35,018 | 35,018 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 1,199 | 1,199 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 3,940 | 59,079 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 3,940 | 3,940 | - | - | Class A Common Stock | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Sale of securities on an exchange or to another person at price $ 7.54 per share. | 25 Oct 2021 | 1,256 | 2,684 | - | 7.5 | 9,470 | Class A Common Stock |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 63,049 | 63,049 | - | - | Restricted Stock Unit | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 42,033 | 42,033 | - | - | Employee Stock Option (Right to Buy) | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 1,114,504 | 1,114,504 | - | - | Employee Stock Option (Right to Buy) | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 401,767 | 401,767 | - | - | Employee Stock Option (Right to Buy) | |
| GeneDx Holdings Corp | Daniel Clark | Secretary and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 13,760 | 13,760 | - | - | Employee Stock Option (Right to Buy) |